Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Provided By GlobeNewswire
Last update: Jul 14, 2025
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025
Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase
Read more at globenewswire.comNASDAQ:DERM (8/18/2025, 2:48:12 PM)
6.96
+0.01 (+0.14%)
NASDAQ:FBIO (8/18/2025, 2:50:28 PM)
2.24
+0.12 (+5.66%)
Find more stocks in the Stock Screener
DERM Latest News and Analysis
